Affiliation:
1. Department of Chemistry; Cleveland State University; Cleveland OH USA
2. Case Comprehensive Cancer Center; Case Western Reserve University; Cleveland OH USA
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry
Reference18 articles.
1. 605 A phase 1, open label, dose-escalation study of oral administration of the investigational agent MLN0128 in combination with paclitaxel (P) in patients (pts) with advanced solid malignancies;Burris;European Journal of Cancer,2012
2. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance;Edlind;Asian Journal of Andrology,2014
3. Abstract C264: effective preclinical treatment of KRAS mutant lung cancers with a combination of MLN0128, an investigational novel mTORC1/2 inhibitor, and a selective MEK inhibitor;Fabrey;Molecular Cancer Therapeutics,2013
4. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models;Gökman-Polar;Breast Cancer Research and Treatment,2012
5. Defining the Role of mTOR in Cancer;Guertin;Cancer Cell,2007
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献